Future of flying being developed in Kamenz

Commercial drones and air cabs will soon no longer be mere fantasies of the future. In order to bring new ideas for tomorrow’s aviation to life, numerous partners together with the city of Kamenz as well as international companies and institutions founded the “Kompetenzzentrum autonomes und elektrisches Fliegen“. The aim is to create the framework Read more about Future of flying being developed in Kamenz[…]

Isotropic Systems Signs Contract with SES GS to Initiate Multi-Orbit Trials of Next-Gen Multi-beam Antenna Technologies for U.S. Military

SES Government Solutions (SES GS), a fully-owned affiliate of SES, and Isotropic Systems, a leading developer of transformational broadband terminal technologies, today announced a two-phased antenna evaluation contract with the U.S. Air Force Research Laboratory, working in close collaboration with the U.S. Army Research Engineering Team, for tests of Isotropic Systems’ multi-beam terminal over SES’s Read more about Isotropic Systems Signs Contract with SES GS to Initiate Multi-Orbit Trials of Next-Gen Multi-beam Antenna Technologies for U.S. Military[…]

Kuros reaches milestone of 2,000 patients treated with MagnetOs bone graft

Strong adoption by spinal surgeons since U.S. launch in September 2019 Sales accelerating with over 2,000 patients treated to date Kuros Biosciences (SIX: KURN) today announced that over 2,000 patients have been treated worldwide with its MagnetOs bone graft, an alternative to the gold standard treatment of autograft. A substantial, and growing, number of clinically Read more about Kuros reaches milestone of 2,000 patients treated with MagnetOs bone graft[…]

Component Design: Competitive Advantage through Stress Analysis

Components are subject to multi-axial loadings. The typical design approach is based on material specific modelling and suitable tests to identify the parameters of the model. The tests are costly and time consuming. Scientists at the Fraunhofer Institute for Structural Durability and System Reliability LBF have suggested a basic approach to select the necessary tests Read more about Component Design: Competitive Advantage through Stress Analysis[…]

4SC AG: 4SC expands avelumab supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer

Combination of domatinostat (HDAC inhibitor) and checkpoint inhibitor avelumab (anti-PD-L1 antibody) to be investigated in a second clinical study in Merkel cell carcinoma (MERKLIN 1 study) 4SC AG (4SC, FSE Prime Standard: VSC) today announced that it has entered into an extension of the supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. for Read more about 4SC AG: 4SC expands avelumab supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer[…]

Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020

Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations  T ime Course of MRI Lesion Suppression Shows Reduction of Lesions Already Present at First Post-Baseline Scan at Week 6, Validating Rapid Attainment of Stable Therapeutic Drug Levels of IMU-838  A Robust Decrease in Serum Neurofilament Light Chain, A Biomarker for Axonal Read more about Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020[…]

4SC and Maruho Discontinue Collaboration for Development of 4SC’s Kv1.3 Inhibitors

Maruho and 4SC agree to terminate their development agreement related to 4SC’s Kv1.3 inhibitors. 4SC to reacquire all rights to the development program. – 4SC AG (4SC, FSE Prime Standard: VSC) today announced that 4SC and Maruho decided to discontinue the collaboration for the development of 4SC’s Kv1.3 inhibitors. As a consequence of this decision Read more about 4SC and Maruho Discontinue Collaboration for Development of 4SC’s Kv1.3 Inhibitors[…]

“TRUSTS” enables European data markets based on the IDS architecture

Data sharing shapes the economic and societal future of Europe and bears huge potentials. But it also comes with risks and apprehensions. The EU project TRUSTS – Trusted Secure Data Sharing Space was established to identify and overcome legal, ethical, and technical challenges of cross-border data markets. The IDS architecture ensures data sovereignty for those Read more about “TRUSTS” enables European data markets based on the IDS architecture[…]

Fighting cardiovascular disease with acne drug

Researchers from the European Molecular Biology Laboratory in Heidelberg and Stanford University have found the cause of dilated cardiomyopathy – a leading cause of heart failure – and identified a potential treatment for it: a drug already used to treat acne. The study was published on 8 September in Cell Reports. The original press release Read more about Fighting cardiovascular disease with acne drug[…]

Chronic Venous Ulcers: Stem cell therapy improves non-healing wounds

The current news is therefore encouraging: In a regulatory agency-approved Phase IIa clinical study, RHEACELL, a company specializing in stem cell therapies, was able to accrue safety and initial efficacy data for ABCB5-positive mesenchymal stem cells (ABCB5+ MSCs) in the treatment of CVU. This study demonstrated successfully that topically applied, highly purified ABCB5+ MSCs modulated Read more about Chronic Venous Ulcers: Stem cell therapy improves non-healing wounds[…]